Targeted Therapeutics Market Size, Share, Growth, and Forecast 2032

Targeted Therapeutics Market Size

Zion Market Research has published a report on the global Targeted Therapeutics Market, estimating its value at USD 108.54 Billion in 2023, with projections indicating that it will reach USD 202.93 Billion by 2032. The market is expected to expand at a compound annual growth rate (CAGR) of 7.2% over the forecast period 2024-2032.

The report explores the factors fueling market growth, the hitches that could hamper this expansion, and the opportunities that may arise in the Targeted Therapeutics Market industry. Additionally, it offers a detailed analysis of how these elements will affect market demand dynamics and market performance throughout the forecast period.

Request Free Sample

Targeted Therapeutics Market: Overview

Targeted therapeutics is a kind of cancer therapy making use of medicines to target cancer tissues without impacting healthy cells. Moreover, these targeted therapies are used in combination with other medicines or conventional therapies for effectively treating cancer. In recent years, personalized cancer treatment with targeted agents is taking center stage and provides personalized treatment to individuals. Apparently, therapeutic peptides are utilized in biomedical applications and they offer high potential in targeting the delivery of medicines owing to its selectivity, biocompatibility, specificity, small dimensions, and modifying ease. Furthermore, in last few years use of tumor-targeting peptides as therapeutics has influenced cancer research & nanotechnology domain.  Additionally, targeted therapeutics have also found slew of applications in breast cancer treatment as well as endometrial cancer therapy. Moreover, myriad types of targeted therapeutics are used for cancer treatment and this includes monoclonal antibodies, small molecular inhibitors, prodrug, and nano-particulate antibody conjugates.

Reportedly, first targeted cancer therapeutics was tamoxifen during 1970. Furthermore, U.S. FDA have approved targeted therapies for cancer that include Xgeva, Votrient, Affinitor, Istodax, Tasigna, Sutent, Zolinza, Sprycel, Rituxan, and Herceptin.

Targeted Therapeutics Market: Growth Factors

Growing focus on cancer drug development and cytotoxic & non-specific chemotherapies has shifted to molecularly targeted and rationally developed medicines which has potential of providing more efficiency with lesser side-effects. This, in turn, will prompt growth of targeted therapeutics market in coming decade. Need for developing specific cancer drugs for treating individuals and necessity of comprehensively understanding genetics & biology of patient will drive targeted therapeutics market trends. Apart from this, shift towards integrated cancer research activities and highlight on biomarker-based & hypothesis-driven clinical trials is expected to create new growth avenues for targeted therapeutics market in near future. Additionally, loophole of chemotherapy is drug resistance & severe side effects on patients. Moreover, way to minimize the chemotherapy effects on healthy cancer tissues of patients is to change bio-distribution of medicine and this can be achieved through passive targeting & active targeting of drugs, thereby steering industry landscape.

Furthermore, targeted therapeutics business is gaining significance owing to its specificity towards cancerous tissues while sparing toxicity to normal as well as off-target cell tissues. Comprehensive understanding of molecular activities underlying cancer in human beings and development of new drugs targeting cancerous cells is anticipated to expedite growth of targeted therapeutics industry over upcoming years. Nevertheless, unmet medical needs and lack of reliability of pre-clinical models for predicting efficacy of cancer treating drugs can impede growth of targeted therapeutics market in foreseeable future.

Targeted Therapeutics Market: Report Scope

Targeted Therapeutics Market: Regional Analysis

Asia Pacific Market To Expand Leaps & Bounds During 2024-2032

Asia Pacific targeted therapeutics market is entering a new era of growth with China possessing huge potential due to success of I-PASS clinical trials on patients in the country. Apart from this, China is slated to play a key role in production of new anti-cancer therapeutic agents, thereby contributing humungously towards regional market size. Furthermore, breakthroughs in pharmacokinetics, cancer biology, and pharmacodynamics along with the development of core capabilities in molecular testing of tumor samples will create new growth opportunities for the targeted therapeutics market in Asia Pacific.

Targeted Therapeutics Market: Competitive Players

Key players profiled in the study and influencing the market growth are

• Amgen, Inc
• Sanofi
• AstraZeneca
• Roche Diagnostics
• Bayer AG
• Novartis AG
• Merck & Co., Inc
• Seagen, Inc
• Pfizer, Inc
• Takeda Pharmaceutical Company Limited
• GlaxoSmithKline plc

The global Targeted Therapeutics Market is segmented as follows:

By Type

• Monoclonal Antibodies
• Small Molecular Inhibitors
• Prodrug
• Nano-Particulate Antibody Conjugates

By Application

• Breast Cancer
• Leukemia
• Lung Cancer
• Colorectal Cancer
• Lymphoma
• Renal Cancer
• Multiple Sclerosis
• Wet Age-Related Macular Degeneration

By Distribution Channel

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa